Do you inject every peptide every day?

Not every peptide is injected daily. Common patterns range from nightly or daily schedules for short-acting compounds to once-weekly schedules for long-acting GLP-1 medicines. The exact interval depends on half-life, mechanism, formulation, and clinical purpose. A prescription label is specific to the dispensed vial and takes priority over a generic peptide calendar.

Why are some peptide injections scheduled at night?

Nighttime scheduling is most often used with short-acting GH-axis peptides. It is intended to place a brief secretagogue signal near the body's normal overnight growth-hormone pulses. Human pharmacokinetic work found an approximately two-hour terminal half-life for ipamorelin, but that result does not prove one universal nightly schedule for every formulation or patient.

What does five days on and two days off mean for peptides?

It means the prescription includes five scheduled administration days followed by two planned days without injections each week. The pattern is used most often with some GH-axis peptides to create a calendar break and preserve pulsatile intent. It is a prescribing convention, not a human-trial finding that applies to every peptide, blend, or clinical situation.

Is TB-500 injected weekly?

Some compounded TB-500 prescriptions use a higher-frequency loading phase followed by weekly maintenance, but no human trial has established that as the optimal TB-500 schedule. A 2026 rat study administered TB-500 daily, underscoring that experimental protocols and human prescriptions are different categories of evidence. The formulation-specific prescription determines the actual frequency.

What happens after a missed peptide injection?

The correct next timing depends on the compound and formulation. A missed nightly secretagogue dose and a missed weekly GLP-1 dose are not handled as if they were the same medication. The label's missed-dose language and the reviewing provider determine whether the schedule resumes, shifts, or requires another plan; an extra injection is not the default.

Can a peptide blend have a different schedule from either ingredient alone?

Yes. A compounded blend is prescribed as the formulation actually dispensed, so its concentration, ingredients, and intended mechanism can produce a schedule different from a single-compound vial. CJC-1295 with DAC also cannot supply the timing for CJC-1295/ipamorelin without DAC. The precise formulation name on the prescription is essential when interpreting frequency.

How Often Do You Inject Peptides?

How often do you inject peptides? Depending on the molecule and formulation, the interval may be nightly, daily, several times per week, or once weekly. Short-acting growth-hormone secretagogues are often scheduled in the evening. BPC-157 protocols commonly use daily administration for a defined course. Long-acting GLP-1 medicines are built for weekly dosing. Frequency follows pharmacology, not personal preference.

The prescription label for the exact preparation takes priority over any general chart. At Promise, a licensed provider reviews every request and not everyone qualifies; the provider sets the interval if a prescription is appropriate.

How often do you inject peptides in common protocols?

There is no single peptide injection frequency. These are patterns a prescriber may write, not directions for self-treatment:

Peptide or category	Pattern seen in practice or research	Why the pattern differs
BPC-157	Often daily for a defined course	Published studies are mostly animal work using repeated administration; human schedule data are very limited
Sermorelin	Commonly nightly, sometimes with planned days off	It is used to create a short growth-hormone-releasing signal rather than continuous exposure
CJC-1295/ipamorelin without DAC	Commonly nightly or on selected evenings	The non-DAC formulation and short ipamorelin signal are designed around pulses
TB-500	Some prescriptions use a higher-frequency loading phase, then weekly maintenance	This is a clinical convention; no human trial has established an optimal TB-500 injection schedule
Long-acting GLP-1 medicines	Once weekly	Molecular engineering extends exposure across the week

The table is a map, not a substitute for the vial label. Even compounds discussed together may have different concentrations, course lengths, or reasons for use. The detailed BPC-157 and TB-500 dosage discussion explains why their schedules should not be treated as interchangeable.

Half-life sets the outer rhythm

Half-life is the time required for the amount of a drug in the body to fall by half. A short half-life usually creates a shorter exposure window. A long half-life can support a wider interval. Mechanism still matters because the biological signal may outlast the measurable drug, and a formulation can deliberately slow absorption or clearance.

In a human pharmacokinetic study, ipamorelin had a terminal half-life of about two hours and produced a single growth-hormone release episode (Gobburu et al., Pharmaceutical Research, 1999). That finding helps explain why prescribers place short-acting GH secretagogues into evening or nightly schedules, but it does not establish one universal home protocol.

The opposite pattern appears with semaglutide. A randomized clinical pharmacology trial measured a half-life of approximately one week, consistent with once-weekly administration (Ikushima et al., Advances in Therapy, 2018). Calling both compounds peptides therefore says almost nothing about how often they are injected.

Formulation names matter too. In a randomized trial, CJC-1295 with a drug-affinity-complex modification had an estimated half-life of 5.8 to 8.1 days (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That long-acting result cannot be transferred to a compounded CJC-1295/ipamorelin blend made without DAC. The CJC-1295/ipamorelin dosage guide owns the formulation-specific detail.

The comparison also shows why a nightly label does not mean a compound must remain measurable all night. With secretagogues, the intended event can be a pulse: in the ipamorelin study, GH peaked about 0.67 hours after exposure and then declined. A prescriber may place that brief input in the evening rather than try to sustain it. When a GHRH analogue and a ghrelin-receptor agonist share one compounded vial, the provider writes one schedule for that exact blend. The frequency cannot be reverse-engineered from whichever ingredient appears to last longest, and a DAC schedule cannot fill in missing instructions for a non-DAC product.

Research schedules are not prescription schedules

BPC-157 and TB-500 show why evidence labels matter. A 2026 controlled rat study administered both compounds daily for four weeks; it did not test a human loading-and-maintenance schedule (Biçer et al., Joint Diseases and Related Surgery, 2026). Earlier BPC-157 ligament work also used once-daily administration in rats (Cerovecki et al., Journal of Orthopaedic Research, 2010). Neither study determines the safest or most effective human injection frequency.

By contrast, a higher-frequency TB-500 loading phase followed by weekly maintenance appears in some compounded prescriptions. That pattern is a clinical convention extrapolated from limited evidence, not the winning schedule from a head-to-head human trial. A prescriber may instead choose a different interval, a finite course, or no prescription at all after weighing the patient, formulation, and evidence.

Why five days on and two days off appears

A five-days-on, two-days-off calendar is most often associated with GH-axis peptides such as sermorelin or short-acting secretagogue blends. The intended logic is to preserve pulsatile signaling and build a regular pause into the week rather than create uninterrupted stimulation. It is not a rule created by the half-life calculation.

There is a biological hypothesis behind the concern about continuous exposure: a rat experiment found that five days of continuous central growth-hormone-secretagogue infusion attenuated the later GH response (Bailey et al., Neuroendocrinology, 1999). That is not evidence that five nights on and two nights off is superior for people using subcutaneous compounded peptides. The break remains a prescribing convention, and different clinicians may reasonably use nightly dosing, selected nights, or a time-limited cycle.

What can change peptide injection frequency

Several facts can change the interval even when the compound name stays the same:

The exact formulation. DAC status, a combination vial, and concentration can change the written plan.
The intended signal. A brief GH pulse, sustained metabolic exposure, and a defined research-derived course are different pharmacologic aims.
Response and monitoring. Side effects, laboratory findings, other medicines, or a change in health can prompt a provider to reassess timing or stop therapy.
A missed injection. The appropriate next time varies by compound; doubling or shifting the calendar is not automatically equivalent.
Course design. “Cycling” may mean days off each week, a treatment period followed by reassessment, or a planned stop. Those are separate decisions.

Mixing and timing are separate questions. How peptide reconstitution works explains vial preparation, while the prescription supplies the actual interval for the dispensed formulation.

The prescription label wins

The safest schedule is the one written for the exact vial after clinical review. If a portal summary, a general article, and a pharmacy label appear to conflict, the label and the reviewing provider are the sources that can resolve the discrepancy. The same is true after a missed injection or a change in side effects.

Which interval is appropriate is a decision for the patient and the reviewing provider, not a preference to settle from a generic chart. Frequency can be nightly, daily, intermittent, or weekly; the peptide name alone never supplies enough information.